AKBA Q2 2025 Earnings — Akebia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AKBAAkebia Therapeutics, Inc.

$365M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$62M+43.1% YoY

Gross Profit

$53M84.1% margin

Operating Income

$14M22.6% margin

Net Income

$247,0000.4% margin

EPS (Diluted)

$0.00

QoQ Revenue Growth

+9.0%

Cash Flow

Operating Cash Flow

$22M

Free Cash Flow

$22M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$346M

Total Liabilities

$316M

Stockholders' Equity

$29M

Cash & Equivalents

$137M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$62M	$44M	+43.1%
Gross Profit	$53M	$35M	+48.7%
Operating Income	$14M	-$9M	+261.5%
Net Income	$247,000	-$9M	+102.9%

Revenue Segments

Product

$60M97%

License Collaboration And Other Revenue

$2M3%